Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion,
First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid
tumors (enriched for grade 2 NENs, grade 2 NETs and NECs) and R/R NHL (MZL, including
transformed MZL). The dose escalation part (Part A) of the study will explore escalating oral
doses of CC-90011 to estimate the maximum tolerated dose (MTD) of CC-90011. The expansion
part (Part B) will further evaluate the safety and efficacy of CC-90011 administered at or
below the MTD in 3 selected expansion cohorts of approximately 10-20 evaluable subjects each,
in order to further define the RP2D.